Technology
Dimerix unveils ‘tremendous’ top-line results for lead drug in treating rare kidney disorder – Small Caps
Drug development company Dimerix (ASX: DXB) emerged from a trading halt today with top-line results from its phase 2a ACTION study into DMX-200 for treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder that often leads to end-stage ki…
Drug development company Dimerix (ASX: DXB) emerged from a trading halt today with top-line results from its phase 2a ACTION study into DMX-200 for treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder that often leads to end-stage kidney failure.
Dimerix received orphan drug designation for DMX-200 in November 2018 in both the US and Europe for the treatment of FSGS, after repurposing the drug based on preliminary non-clinical data which showed a reduction in the numbe…
-
General22 hours agoHow they started and how they finished • Inside Story
-
Noosa News22 hours agoAustralian farmers express ‘profound disappointment’ as tariffs on Aussie beef backfires on Americans
-
Business21 hours agoWhich ASX sectors led the pack in March, according to Macquarie?
-
Noosa News24 hours agoHonour awarded at cocktail party – Proctor